Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6427MR)

This product GTTS-WQ6427MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6427MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1917MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ15605MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ9327MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ6916MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ3602MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ14722MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ1873MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ3746MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW